The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 401–500 of 857
Druggable Lysophospholipid Signaling Pathways
Yanagida, K., & Valentine, W. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_7 · Cited by 27
Lee, C., Sapkota, A., Gaire, B. P., & Choi, J. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228595 · Cited by 26
Nikitopoulou, I., Fanidis, D., Ntatsoulis, K., Moulos, P., Mpekoulis, G., Evangelidou, M., Vassiliou, A. G., Dimakopoulou, V., Jahaj, E., Tsipilis, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810006 · Cited by 27
“Single-cell RNA sequencing (scRNAseq) analysis and transcriptional profiling indicated similarities in expression profiles between idiopathic pulmonary fibrosis (IPF) and COVID-19 [13,14], while CoV-2 infection has been suggested to stimulate the expression of major pro-fibrotic factors including TGFβ [15].”
BackgroundInfluentialAblation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model
Raja, A. A., Wakimoto, H., DeLaughter, D. M., Reichart, D., Gorham, J., Conner, D. A., Lun, M., Probst, C. K., Sakai, N., Knipe, R. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204174119 · Cited by 27
“Genetic ablation or pharmacologic antagonism of LPAR1 ameliorates progression of pulmonary fibrosis by attenuating fibroblast migration and activation, epithelial cell apoptosis, and vascular leak (20).”
BackgroundSelf-citationNeighbors, M., Li, Q., Zhu, S., Liu, J., Wong, W. R., Jia, G., Sandoval, W. N., & Tew, G. W. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100375 · Cited by 26
“Consistently, the deletion of the LPA1 receptor reduced vascular leakage in a bleomycin mouse model of fibrosis (10).”
BackgroundInfluentialZhao, J., Chen, Q., Li, H., Myerburg, M. M., Spannhake, E. W., Natarajan, V., & Zhao, Y. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.004 · Cited by 26
Functional genomic screen identifies novel mediators of collagen uptake
Lee, T., McKleroy, W., Khalifeh‐Soltani, A., Sakuma, S., Lazarev, S., Riento, K., Nishimura, S. L., Nichols, B. J., & Atabai, K. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-07-0382 · Cited by 26
Evaluation and management approaches for scleroderma lung disease
Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 28
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 27
Macisaac, S., Somboonviboon, D., Scallan, C. J., & Kolb, M. R. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2340723 · Cited by 28
“In bleomycin models of pulmonary fibrosis LPA levels were increased in bronchoalveolar lavage fluid while LPA 1 knockout mice and an oral LPA 1 receptor antagonist had reduced fibrosis post bleomycin [41,42].”
BackgroundMethodEmerging therapeutic interventions for idiopathic pulmonary fibrosis
Chakraborty, S., Chopra, P., Ambi, S. V., Dastidar, S. G., & Ray, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.913569 · Cited by 29
Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 26
Matsuzaki, S., Ishizuka, T., Hisada, T., Aoki, H., Komachi, M., Ichimonji, I., Utsugi, M., Ono, A., Koga, Y., Dobashi, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000904 · Cited by 25
Wan, R., Wang, L., Duan, Y., Zhu, M., Li, W., Zhao, M., Yuan, H., Xu, K., Li, Z., Zhang, X., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01702-9 · Cited by 25
Diverse effects of LPA receptors on cell motile activities of cancer cells
Tsujiuchi, T., Hirane, M., Dong, Y., & Fukushima, N. (2014) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2013.876042 · Cited by 24
“postinjury bronchoalveolar lavage (7).”
BackgroundMirzoyan, K., Baïotto, A., Dupuy, A., Marsal, D. J., Denis, C., Vinel, C., Sicard, P., Bertrand‐Michel, J., Bascands, J., Schanstra, J. P., et al. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0518-0 · Cited by 24
Cai, J., Wei, J., Li, S., Suber, T. L., & Zhao, J. (2017) · Mediators of Inflammation · doi:10.1155/2017/6893560 · Cited by 24
“Studies have shown that LPA levels in bronchoalveolar lavage (BAL) fluid increase in idiopathic pulmonary fibrosis (IPF) patients [2, 9, 10].”
BackgroundChen, X., Walther, F. J., Laghmani, E. H., Hoogeboom, A. M., Hogen-Esch, A. C. B., van Ark, I., Folkerts, G., & Wagenaar, G. T. M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00155 · Cited by 24
Yano, R., Ma, L., Nagai, J., & Ueda, H. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9970-3 · Cited by 23
Chen, X., Walther, F. J., van Boxtel, R., Laghmani, E. H., Sengers, R. M. A., Folkerts, G., DeRuiter, M. C., Cuppen, E. P. J. G., & Wagenaar, G. T. M. (2015) · Acta Physiologica · doi:10.1111/apha.12622 · Cited by 23
“Beneficial effects of reduced LPAR1 signalling in pulmonary disease have been demonstrated in fibroblasts of patients with idiopathic pulmonary fibrosis (Tager et al. 2008) and in rodents, as LPAR1-deficient mice are protected against fibrosis and mortality after bleomycin-induced pulmonary fibrosis (Tager et al.”
BackgroundResultInfluentialThe development of modulators for lysophosphatidic acid receptors: A comprehensive review
Liu, W., Hopkins, A. M., & Hou, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105386 · Cited by 23
Fusco, R., Siracusa, R., D’Amico, R., Cordaro, M., Genovese, T., Gugliandolo, E., Peritore, A. F., Crupi, R., Paola, R. D., Cuzzocrea, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207761 · Cited by 23
RetractedAdvances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Brazee, P. L., Allen, N., Knipe, R. S., Redente, E. F., & Saux, C. J. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9402 · Cited by 27
Yamamura, Y., Sakai, N., Iwata, Y., Lagares, D., Hara, A., Kitajima, S., Toyama, T., Miyagawa, T., Ogura, H., Sato, K., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201870r · Cited by 23
Self-citationTiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway
Costa, L., Roth, M., Miglino, N., Keglowich, L., Zhong, J., Lardinois, D., Tamm, M., & Borger, P. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.11.001 · Cited by 22
Piednoir, P., Quesnel, C., Nardelli, L., Leçon-Malas, V., Bouadma, L., Lasocki, S., Philip, I., Mailleux, A., Soler, P., Crestani, B., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31824e65ba · Cited by 22
Rosethorne, E. M., & Charlton, S. J. (2018) · Journal of Experimental Pharmacology · doi:10.2147/jep.s159124 · Cited by 25
“47,48 The chemotactic assay is based on the original Boyden Assay 49 and uses plastic inserts that contain a cell-permeable membrane, such as the Transwell ® Permeable Supports, that are placed in multiwell plates.”
Dacheux, M. A., Norman, D. D., Tigyi, G., & Lee, S. Ç. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108414 · Cited by 21
Yoon, D., Choi, B., Kim, J.-E., Kim, E., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E., & Song, J. (2024) · BMC Medicine · doi:10.1186/s12916-024-03342-x · Cited by 21
“…the ATX-LPA axis has emerged as a novel regulator of multiple molecular pathways and has been strongly implicated in a variety of physiological and pathological processes, including pulmonary fibrosis [48, 49], neuropathic pain [50], cardiovascular disease [51], and tumor progression [52–56].”
BackgroundLysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts
Yin, Z., Carbone, L. D., Gotoh, M., Postlethwaite, A. E., Bolen, A. L., Tigyi, G., Murakami‐Murofushi, K., & Watsky, M. A. (2010) · Rheumatology · doi:10.1093/rheumatology/keq260 · Cited by 21
Jiang, C. C., Tong, Z., Fang, W., Fu, Q., Gu, Y., Lv, T., Liu, D., Xue, W., & Lv, J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26610 · Cited by 22
RetractedVerdoorn, K. S., Lindoso, R. S., Lowe, J., Lara, L. S., Vieyra, A. R., & Einicker‐Lamas, M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq286 · Cited by 22
Effects of lysophosphatidic acid and its receptors LPA__AMB__frac13; on radiation pneumonitis
Lü, Y. (2010) · Oncology Reports · doi:10.3892/or_00001013 · Cited by 21
Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain
Rivera, R. R., Lin, M., Bornhop, E. C., & Chun, J. J. M. (2020) · The FASEB Journal · doi:10.1096/fj.202000317r · Cited by 21
Self-citationVascular involvement in idiopathic pulmonary fibrosis
Mondoni, M., Rinaldo, R. F., Ryerson, C. J., Albrici, C., Baccelli, A., Tirelli, C., Marchetti, F., Cefalo, J., Nalesso, G., Ferranti, G., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00550-2024 · Cited by 21
The roles of fused-cyclopropanes in medicinal chemistry: Insights from the past decade
Li, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117951 · Cited by 22
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
“There is also a report that LPA/LPA1 signals affected the vascular endothelial cells, resulting in exacerbation of the vascular permeability in LPA1 KO mice [108].”
BackgroundInfluentialLysophospholipid mediators in the vasculature
Mueller, P., Ye, S., Morris, A. J., & Smyth, S. S. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.03.016 · Cited by 20
“response to inflammatory stimuli in the lung [16] and the skin [17].”
BackgroundPossible Role of Lysophosphatidic Acid in Rat Model of Hypoxic Pulmonary Vascular Remodeling
Shlyonsky, V. G., Naeije, R., & Mies, F. (2014) · Pulmonary Circulation · doi:10.1086/677362 · Cited by 20
“However, little is known about the effect of increased LPA concentration in the blood, although indirect data suggest that high LPA is deleterious.(11,12) This lipid”
BackgroundCarter, C. L., Jones, J. W., Barrow, K. R., Kieta, K. M., Taylor-Howell, C., Kearney, S. R., Smith, C. P., Gibbs, A. M., Farese, A. M., MacVittie, T. J., et al. (2015) · Health Physics · doi:10.1097/hp.0000000000000353 · Cited by 20
“For example, LPA has been shown to mediate fibroblast migration and recruitment as well as increase vascular permeability in a bleomycin mouse model of fibrosis, highlighting the impact these small molecular weight lipids have on disease progression (Tager et al. 2008).”
BackgroundGallezot, J., Nabulsi, N., Holden, D., Lin, S.-F., Labaree, D. C., Ropchan, J. R., Najafzadeh, S., Donnelly, D. J., Cao, K., Bonacorsi, S. J., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195073 · Cited by 20
“In IPF, the concentration of lysophosphatidic acid is increased in the bronchoalveolar lavage fluid, and LPA1-expressing fibroblasts are present, whereas they are absent in healthy controls (4).”
BackgroundTherapeutic targets and early stage clinical trials for pulmonary fibrosis
Sato, S., Yanagihara, T., & Kolb, M. R. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1554054 · Cited by 20
“The genetic deletion of LPA1 attenuates bleomycin-induced lung fibrosis in mice via reduced fibroblast recruitment and vascular leak [23].”
BackgroundManagement of Idiopathic Pulmonary Fibrosis
Salisbury, M. L., & Wijsenbeek, M. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.004 · Cited by 20
Protective role of cortistatin in pulmonary inflammation and fibrosis
Barriga, M., Benítez, R., Ferraz-de-Paula, V., García-Frutos, M., Caro, M., Robledo, G., O’Valle, F., Campos‐Salinas, J., & Delgado, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15615 · Cited by 20
“Cell pellets were resuspended in PBS and used to determine total cell numbers using a standard haemocytometer and to analyse the percentage of neutrophils, macrophages and T lymphocytes in BALF by flow cytometry as described below (Tager et al., 2008).”
MethodActivation of the ATX/LPA/LPARs axis induces a fibrotic response in skeletal muscle
Córdova-Casanova, A., Cruz-Soca, M., Chun, J. J. M., Casar, J. C., & Brandan, E. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.03.008 · Cited by 21
Self-citationShewchuk, B. M. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.09.005 · Cited by 21
“LPA stimulates cell proliferation involved in brain development and early embryonic growth, and is involved in processes including inflammation, neuropathic pain and lung fibrosis [13–15].”
BackgroundThe Future of Boron in Medicinal Chemistry: Therapeutic and Diagnostic Applications
Draganov, A. B., Wang, D., & Wang, B. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_65 · Cited by 20
Zhu, S., Gladson, C. L., White, K. E., Ding, Q., Stewart, J. E., Jin, T. H., Chapman, H. A., & Olman, M. A. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90283.2008 · Cited by 20
Autotaxin and lysophosphatidic acid signalling in lung pathophysiology
Magkrioti, C. (2013) · World Journal of Respirology · doi:10.5320/wjr.v3.i3.77 · Cited by 20
Brown, A. D., Hossain, I., Perez, L. J., Nzirorera, C., Tozer, K., D’Souza, K., Trivedi, P. C., Aguiar, C., Yip, A. M., Shea, J. L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189402 · Cited by 21
Tomos, I. P., Kanellopoulou, P., Nastos, D., & Aidinis, V. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2471579 · Cited by 20
“The pathologic effects of ATX are attributed to the local production of LPA and the induction of LPAR1-mediated signaling, leading to epithelial apoptosis, vascular leaks, and the accumulation of fibroblasts [73,74].”
Autotaxin-LPA receptor axis in the pathogenesis of lung diseases.
Chu, X., Wei, X., Lu, S., & He, P. (2015) · PubMed · Cited by 19
The Pulmonary Toxicity of Anticancer Agents
Yoneda, K. Y., & Cross, C. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00924-6 · Cited by 19
New treatment directions for IPF: current status of ongoing and upcoming clinical trials
Macagno, F., Varone, F., Leone, P. M., Mari, P., Panico, L., Berardini, L., & Richeldi, L. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335601 · Cited by 19
“LPA pathway was supposed to be a therapeutic target for IPF already in 2008 by Tager and coworkers [18], based on the important role played in fibroblast chemotaxis and the elevated levels in bronchoalveolar lavage fluid (BALF) of patients”
BackgroundResultInfluentialFeng, Z., Wang, J., Wang, Y., Dong, W., & Xu, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.915417 · Cited by 19
“We calculated capillary permeability of lungs in animals by Evans blue dye extravasation, by a method previously published [20].”
MethodFrom pathogenesis to therapy – Perspective on treatment strategies in fibrotic diseases
Ramming, A., Dees, C., & Distler, J. H. W. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.012 · Cited by 19
MiR-338* suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1.
Zhuang, Y., Dai, J., Wang, Y., Zhang, H., Li, X., Wang, C., Cao, M., Liu, Y., Cai, H., Zhang, D., et al. (2016) · Europe PMC (PubMed Central) · Cited by 20
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis
Simonetti, J., Ficili, M., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2305126 · Cited by 18
“…acid (ATX-LPA) signaling pathway has received increasing attention as a promising target for therapeutic intervention in a variety of diseases, such as tumor metastasis [19,20], fibrosis diseases [21,22], pruritus [23], chronic inflammatory disorders [24,25] and among others.”
BackgroundUpdates on animal models of systemic sclerosis
Soare, A., Ramming, A., Avouac, J., & Distler, J. H. W. (2016) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000220 · Cited by 21
“The mechanisms for bleomycin-induced tissue injury and fibrosis are complex, including a variety of profibrotic mediators including the stem-cell pathways Wnt, Notch, Hedgehog; transforming growth factor beta (TGF-β) and its activator avb6 integrin; innate immune and inflammasome mediators such as IL-1, IL-6, HMGB1; a…”
BackgroundSpagnolo, P. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_11 · Cited by 18
New Directions in the Study and Treatment of Metastatic Cancer
Yoo, B., Fuchs, B. C., & Medarova, Z. O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00258 · Cited by 18
“ATX/LPA signaling is an important driver of pulmonary (96), renal (97), and liver fibrosis (98).”
BackgroundUncovering unique roles of LPA receptors in the tumor microenvironment
Lee, S.-C., Fujiwara, Y., & Tigyi, G. (2015) · Receptors & Clinical Investigation · doi:10.14800/rci.440 · Cited by 18
“These authors also reported abundant expression of LPA2 and LPA5 in CD4 and CD8 T lymphocytes ([20]).”
Rancoule, C., Espenel, S., Trone, J., Langrand-Escure, J., Vallard, A., Rehailia-Blanchard, A., Hamrouni, A. E. M., Xia, Y., Guy, J., Mrad, M. B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16672 · Cited by 19
“com/oncotarget exposure to bleomycine, lung collagene, peribronchiolar and parenchymal fibrosis were significantly decreased in LPA1R-deficient mice versus wild type ones [46].”
BackgroundEmerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“Lysophosphatidic acids (LPA) are highly active in wound healing and scar formation/collagen deposition in the wound healing process – they induce fibroblast activation, proliferation, and migration, and have been found to boost apoptosis of pulmonary epithelial cell in response to injury [104].”
Sivaraman, L., Gill, M., Nelson, D. M., & Chadwick, K. D. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115846 · Cited by 17
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways
Carriera, L., Lipsi, R., Dodaj, M., Inchingolo, R., Smargiassi, A., Coppola, A., Mari, P., Barone, R., Ielo, S., Scala, R., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14010154 · Cited by 20
“The LPA signaling axis is involved in a variety of physiological and pathological processes, including cell migration, proliferation, survival, angiogenesis, and, notably, fibrosis [51].”
Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA1
Olianas, M. C., Dedoni, S., & Onali, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172963 · Cited by 20
Shedding light on developmental drugs for idiopathic pulmonary fibrosis
Spagnolo, P., Bonella, F., Ryerson, C. J., Τzouvelekis, Α., & Maher, T. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1782885 · Cited by 17
Kondo, M., Tezuka, T., Ogawa, H., Koyama, K., Bando, H., Azuma, M., & Nishioka, Y. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000509804 · Cited by 17
The Many Roles of Lysophospholipid Mediators and Japanese Contributions to This Field
Takagi, Y., Nishikado, S., Omi, J., & Aoki, J. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00304 · Cited by 17
Berdichevets, I. N., Tyazhelova, T. V., Shimshilashvili, K. R., & Rogaev, E. I. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910090026 · Cited by 17
Gan, X., Wang, C., Patel, M. R., Kreutz, B., Zhou, M. Y., Kozasa, T., & Wu, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.477406 · Cited by 17
“LPA induces diverse cellular responses, including proliferation, adhesion, migration, morphogenesis, differentiation, and survival (13), and has an important role in pulmonary fibrosis (14).”
BackgroundColín‐Santana, C. C., Avendaño-Vázquez, S. E., Alcántara-Hernández, R., & García-Sáinz, J. A. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.08.016 · Cited by 17
Ziehr, D. R., Li, F., Parnell, K. M., Krah, N. M., Leahy, K. J., Guillermier, C., Gao, C., Prell, S. A., Vigder, N., Poli, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ads2673 · Cited by 17
RGS2 and female common diseases: a guard of women’s health
Xu, Q., Yao, M., & Tang, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04462-3 · Cited by 16
“Intriguingly, some G q -coupled GPCRs and their corresponding ligands are significantly actuated of pulmonary fibrosis, such as lysophosphatidic acid receptor 1, protease-activated receptor-1 (PAR1), and endothelin receptors [105–108].”
BackgroundLescop, C., Birker, M., Brotschi, C., Bürki, C., Morrison, K., Froidevaux, S., Delahaye, S., Nayler, O., & Bolli, M. H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01827 · Cited by 16
Liu, J.-Q., Zhou, H.-B., Bai, W., Wang, J., Li, Q., Fan, L., Chang, H. S., & Shi, S. (2024) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2024.2326616 · Cited by 16
Reexamining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis
O’Callaghan, M., Tarling, E. J., Bridges, J. P., Redente, E. F., Byrne, A. J., Keane, M. P., & McCarthy, C. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0124ps · Cited by 16
Zhou, Q., Chen, Y., Liang, Y., & Sun, Y. (2024) · Metabolites · doi:10.3390/metabo14060317 · Cited by 19
“In LPAR1 knockout (KO) mice, bleomycin-induced fibrosis is notably reduced, the hydroxyproline content in the lungs significantly decreases, and the 21-day survival rate markedly improves [71].”
BackgroundInfluentialBeyond TGFβ – Novel ways to target airway and parenchymal fibrosis
Boorsma, C. E., Dekkers, B. G. J., van Dijk, E. M., Kumawat, K., Richardson, J., Burgess, J. K., & John, A. E. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.08.009 · Cited by 18
“LPA1R-mediated vascular leakage and increased fibroblast recruitment [219].”
BackgroundFu, S., & Davies, K. P. (2015) · International Journal of Impotence Research · doi:10.1038/ijir.2015.5 · Cited by 16
“While A1 and A3 are associated with G i and inhibit adenylate cyclase activity (25), A2A and A2B are coupled to G s and activate adenylate cyclase (26).”
The lysophosphatidic acid axis in fibrosis: Implications for glaucoma
O’Regan, A., O'Brien, C. J., & Eivers, S. B. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12929 · Cited by 16
“ATX and LPA are present at very high levels in both human and animal models of organ fibrosis.(60,95) ATX expression is increased by inflammatory cytokines tumour necrosis factor (TNF) and interleukin-1β (IL1β).”
BackgroundInfluentialSattikar, A., Dowling, M. R., & Rosethorne, E. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13671 · Cited by 16
“Fibroblast chemotaxis to LPA has also been shown to occur via the PTx-sensitive Gi/o proteins (Tager et al., 2008), whereas the G12/13-RhoA pathway is responsible for actin cytoskeleton rearrangements in fibroblasts (Sakai et al.”
BackgroundInfluentialKreuter, M., Maher, T. M., Wuyts, W. A., Valenzuela, C., Hamblin, M., Kim, S., Patel, A., Elpers, B., & Richeldi, L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.04.003 · Cited by 15
Investigational drugs for idiopathic pulmonary fibrosis
Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15
“in bronchoalveolar lavage fluid (BALF) from IPF patients have been found to be elevated [19], as well as ATX levels resulted to be increased in lung tissue from IPF patients [20].”
Background[Retracted] Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
Kou, L., Kou, P., Luo, G., & Wei, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6197219 · Cited by 15
“The activation of LPA receptor LPA1 is associated with vascular leakage and increased fi broblast aggregation [123].”
RetractedTargeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)
Gu, Z., Yan, Y., Yao, H., Lin, K., & Li, X. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2130753 · Cited by 16
Beukes, D., van Reenen, M., Loots, D. T., & du Preez, I. (2023) · Metabolomics · doi:10.1007/s11306-023-02017-7 · Cited by 15
Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis
Huang, W., Chuang, C.-F., Huang, Y.-T., Chung, I., Chen, M.-L., Chuang, T., Yang, X., Chou, Y.-Y., Liu, C.-H., Chen, N., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02583-3 · Cited by 15
“Since fibroblast recruitment in response to lung injury also leads to fibrosis [15], we therefore hypothesized ENO1 might possess pro-fibrotic effects via facilitating monocytes and fibroblasts trafficking in lung fibrosis.”
Background“Regression to the truth”: lessons learned from negative IPF trials
Trachalaki, A., Lindahl, A. L., Petrarulo, S., & Margaritopoulos, G. A. (2025) · Breathe · doi:10.1183/20734735.0260-2024 · Cited by 15
Sinclair, K. A., Yerkovich, S. T., Hopkins, P. M.-A., Fieuw, A. M., Ford, P., Powell, J. E., O’Sullivan, B., & Chambers, D. C. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.10.005 · Cited by 15
Wu, Z., Zhu, L., Nie, X., Liu, Y., Zhang, X., & Qi, Y. (2023) · Respiratory Research · doi:10.1186/s12931-023-02382-w · Cited by 15
Activation of skeletal muscle FAPs by LPA requires the Hippo signaling via the FAK pathway
Cruz-Soca, M., Faundez-Contreras, J., Córdova-Casanova, A., Gallardo, F. S., Bock-Pereda, A., Chun, J. J. M., Casar, J. C., & Brandan, E. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.03.010 · Cited by 15
Self-citationShakeel, I., Afzal, M., Islam, A., Sohal, S. S., & Hassan, M. I. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100167 · Cited by 16
Sidduri, A., Budd, D. C., Fuentes, M. E., Lambros, T., Ren, Y., Roongta, V. A., Schoenfeld, R. C., Gillespie, P., Stevenson, C. S., Truitt, T., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.001 · Cited by 15
Seeing the future of bioactive lipid drug targets
Evans, J. F., & Hutchinson, J. H. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.394 · Cited by 16
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Identification of compounds acting as negative allosteric modulators of the LPA1 receptor
Ellery, J. M., Dickson, L., Cheung, T., Ciuclan, L. I., Bunyard, P., Mack, S. R., Buffham, W. J., Farnaby, W., Mitchell, P., Brown, D., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.040 · Cited by 15
Claudino, M. A., & Fertrin, K. Y. (2012) · Anemia · doi:10.1155/2012/723520 · Cited by 16
“Adenosine-induced vasodilation is mediated by increasing intracellular cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle cells via A2 receptor signaling [62, 63].”
Background
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.